Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. |
| |
| Authors: | M Schmidinger C Wenzel G J Locker F Muehlbacher R Steininger M Gnant R Crevenna A C Budinsky |
| |
| Affiliation: | Department of Internal Medicine I, Division of Clinical Oncology, University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. |
| |
| Abstract: | We performed a pilot-study on pegylated liposomal doxorubicin (PLD) for advanced hepatocellular carcinoma. Seventeen patients received 40 mg/m(2) PLD intravenously every 4 weeks. A clinical benefit response was achieved in 50% (complete remission 7%, minor remission 7%, stable disease 36%). Toxicities were moderate. In view of these encouraging findings, further studies appear warranted. |
| |
| Keywords: | hepatocellular carcinoma liposomal doxorubicin chemotherapy toxicity survival |
|
|
